From the ODYSSEY OUTCOMES trial, we have learned that the outcome of the PCSK9 inhibitor arm versus the control arm differs much more widely in patients with polyvascular than in those with monovascular or bivascular disease [31]. This evidence concerns the gene PCSK9 and glycogen storage disease VI.